20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta
The annual CROI continues to be the most important HIV scientific meeting covering the diversity of basic and clinical science.
Also, both the main conference and a pre-meeting programme of lectures for new investigators are promptly posted online as open access webcasts.
This year the meeting resulted in wide press coverage of the case of a baby who appears functionally cured following 18 months treatment initiated within two days of birth. But the conference included a wealth of other studies covering HIV treatment and prevention. This included studies reporting new drugs, new strategies (especially treatment during early infection), paediatrics, TB and other OIs – principally in resource limited settings – and exciting results for hepatitis C coinfection.
Reports in this issue of HTB include:
- ARV pipeline: dolutegravir, TAF (GS-7340), MK-1439 and cenicriviroc
- ARV pipeline: long-acting formulations – rilpivirine, GSK-744 and nanoformulations
- Five-year results from the AntiRetroviral Research for Watoto (ARROW) Trial
- Comparison of ritonavir-boosted lopinavir or NNRTI ART and PK with antimalarials in Ugandan children
- Pharmacokinetics and acceptability of lopinavir/ritonavir sprinkles in children aged 1 to 4 years
- Pharmacokinetics of currently available antiretroviral options for young children
- Safety of transplacental raltegravir in neonates and washout pharmacokinetics
- Tenofovir use in children
- ddI resistance in South African children failing an abacavir or d4T based first-line regimen
- Statin use in HIV positive people
- RIFAQUIN study demonstrates once-weekly dosing during continuation phase of TB treatment
- Study indicates rifampicin dose should be higher
- Counter-intuitive result of IPT plus ART trial
- Combining Xpert and LAM urine testing improves TB diagnostic sensitivity
- Deferring ART by four weeks reduces mortality in patients diagnosed with cryptococcal meningitis
- Monthly injection protects macaques from rectal exposure: results should fast-track human studies for advanced PrEP options
- Tenofovir DF ring protects macaques from vaginal exposure
- VOICE study reports low adherence as reason for lack of efficacy for PrEP: anal sex common in African heterosexuals
- Further studies on how male circumcision may reduce HIV transmission
- Report of a functional cure in an HIV infected infant
Further reports will be continue in the next issue of HTB, with pre- press articles available earlier online.
Unless stated otherwise, references are to the Programme and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta.